Research in Experimental Medicine

, Volume 169, Issue 3, pp 175–187 | Cite as

Studies on the percutaneous absorption of3H-Aescin in Pigs



Percutaneous absorption of aescin was measured following application of an aqueous solution of tritiated sodium aescinate to the ventral skin of pigs. Following single or repeated application at various intervals, the concentration of total activity, non-volatile activity and aescin activity following TLC was determined in different organs, tissues, blood and urine.

Very high concentrations of aescin were found in skin and muscular tissues underlying the application site. Only low values were measured in internal organs, blood, urine, skin and musculature from other parts of the body. The concentration of non-volatile activity in subcutis is 50–600 and in musculature 10–50 times higher than in blood.

Only 0.5 – 1% is excreted in urine within 24 hours of administration. The calculated total elimination (bile + urine) may be 1 – 2.5% of the dose. Barely one half is excreted as native aescin, the rest as volatile activity and different metabolites.

Key words

Aescin percutaneous absorption pig 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bartek, M.J., LaBudde, J.A., Maibach, H.I.: J. invest. Derm.58 114–123 (1972)PubMedGoogle Scholar
  2. 2.
    Bethke, S.: Therapiewoche14 671 (1969)Google Scholar
  3. 3.
    Bray, G.A.: Anal. Biochem.1 279–285 (1960)Google Scholar
  4. 4.
    Hackländer, Th.: Dissertation, Tierärztl. Hochschule Hannover (1972)Google Scholar
  5. 5.
    Jakob, F., Fassbender, B.: Fortschr. Med.87 893–894 (1969)Google Scholar
  6. 6.
    James, M., Marty, J.-P., Wepierre, J.: C.R. Acad. Sci. (D) (Paris)278 2063–2066 (1974)Google Scholar
  7. 7.
    James, M., Wepierre, J.: Ann. Pharm. franç.32 633–640 (1974)Google Scholar
  8. 8.
    James, M., Marty, J.-P., Wepierre, J.: C.R. Acad. Sci. (D) (Paris)281 1525–1528 (1975)Google Scholar
  9. 9.
    Lang, W., Mennicke, W.H.: Arzneim.-Forsch. (Drug Res.)22 1928–1932 (1972)Google Scholar
  10. 10.
    Lang, W.: Arzneim.-Forsch. (Drug Res.)24 71–76 (1974)Google Scholar
  11. 11.
    Lorenz, D., Reiffer, F.: Arzneim.-Forsch. (Drug Res.)17 1083–1085 (1967)Google Scholar
  12. 12.
    Ludwig, H.: Med. Welt21 194–196 (1970)Google Scholar
  13. 13.
    Michael, R.J.: Ärztl. Prax.22 4863–4864 (1970)Google Scholar
  14. 14.
    Montagna, W., Yun, J.S.: J. invest. Derm.43 11–21 (1964)Google Scholar
  15. 15.
    Müscher, C.-H.: Ärztl. Prax.22 970–972 (1970)Google Scholar
  16. 16.
    Potzel, J.G., Potzel, G.D.: Ärztl. Prax.22 2809–2811 (1970)Google Scholar
  17. 17.
    Przerwa, M., Arnold, M.: Arzneim.-Forsch. (Drug Res.)25 1048–1053 (1975)Google Scholar
  18. 18.
    Reis, H.: Ärztl. Prax.21 3033 (1969)Google Scholar
  19. 19.
    Saalbach, R.: Ärztl. Prax.22 3222–3224 (1970)Google Scholar
  20. 20.
    Wagner, J., Schlemmer, W., Hoffmann, H.: Arzneim.-Forsch. (Drug Res.)20 205–209 (1970)Google Scholar
  21. 21.
    Wagner, J., Hoffmann, H., Löw, J.: Hoppe-Seylers Z. physiol. Chem.351 1133–1140 (1970)PubMedGoogle Scholar
  22. 22.
    Wulff, G., Tschesche, R.: Tetrahedron25 415–436 (1969)PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • W. Lang
    • 1
  1. 1.Biologisches InstitutFirma Dr. Madaus & Co.Köln 91Federal Republic of Germany

Personalised recommendations